Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19.
Curr Pharm Des
; 28(12): 948-968, 2022.
Article
in English
| MEDLINE | ID: covidwho-1484937
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus responsible for the current global pandemic, which first emerged in December 2019. This coronavirus has affected 217 countries worldwide, most of which have enacted non-remedial preventive measures, such as nationwide lockdowns, work from home, travel bans, and social isolation. Pharmacists, doctors, nurses, technologists, and other healthcare professionals have played pivotal roles during this pandemic. Unfortunately, confirmed drugs have not been identified for the treatment of patients with coronavirus disease 2019 (COVID-19) caused by SARSCoV2; however, favipiravir and remdesivir have been reported as promising antiviral drugs. Some vaccines have already been developed, and vaccination is ongoing globally. Various nanotechnologies are currently being developed in many countries for preventing SARS-CoV-2 spread and treating COVID-19 infections. In this article, we present an overview of the COVID-19 pandemic situation and discuss nanotechnology-based approaches and investigational therapeutics for COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Curr Pharm Des
Journal subject:
Pharmacy
Year:
2022
Document Type:
Article
Affiliation country:
1381612827666210701150315
Similar
MEDLINE
...
LILACS
LIS